FUSION-guided hypothesis development leads to the identification of N6,N6-dimethyladenosine, a marine-derived AKT pathway inhibitor

Rachel M. Vaden, Nathaniel W. Oswald, Malia B. Potts, John B. MacMillan, Michael A. White

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harnessing this diversity for biomedical benefit is limited by challenges associated with natural product purification and determination of biochemical mechanism. Using Functional Signature Ontology (FUSION), we report the parallel isolation and characterization of a marine-derived natural product, N6,N6-dimethyladenosine, that robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. Upon validation of the elucidated structure by comparison with a commercially available sample, experiments were initiated to understand the small molecule's breadth of effect in a biological setting. One such experiment, a reverse phase protein array (RPPA) analysis of >50 kinases, indicated a specific cellular response to treatment. In all, leveraging the FUSION platform allowed for the rapid generation and validation of a biological mechanism of action hypothesis for an unknown natural product and permitted accelerated purification of the bioactive component from a chemically complex fraction.

Original languageEnglish (US)
Article number75
JournalMarine Drugs
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Biological Products
Protein Array Analysis
Non-Small Cell Lung Carcinoma
Phosphotransferases
Bacteria
Cell Line
Pharmaceutical Preparations

Keywords

  • AKT
  • Dimethyladenosine
  • Functional signature ontology

ASJC Scopus subject areas

  • Drug Discovery

Cite this

FUSION-guided hypothesis development leads to the identification of N6,N6-dimethyladenosine, a marine-derived AKT pathway inhibitor. / Vaden, Rachel M.; Oswald, Nathaniel W.; Potts, Malia B.; MacMillan, John B.; White, Michael A.

In: Marine Drugs, Vol. 15, No. 3, 75, 01.03.2017.

Research output: Contribution to journalArticle

@article{edd70f12de7f4ec68f02a9bdce1e5236,
title = "FUSION-guided hypothesis development leads to the identification of N6,N6-dimethyladenosine, a marine-derived AKT pathway inhibitor",
abstract = "Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harnessing this diversity for biomedical benefit is limited by challenges associated with natural product purification and determination of biochemical mechanism. Using Functional Signature Ontology (FUSION), we report the parallel isolation and characterization of a marine-derived natural product, N6,N6-dimethyladenosine, that robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. Upon validation of the elucidated structure by comparison with a commercially available sample, experiments were initiated to understand the small molecule's breadth of effect in a biological setting. One such experiment, a reverse phase protein array (RPPA) analysis of >50 kinases, indicated a specific cellular response to treatment. In all, leveraging the FUSION platform allowed for the rapid generation and validation of a biological mechanism of action hypothesis for an unknown natural product and permitted accelerated purification of the bioactive component from a chemically complex fraction.",
keywords = "AKT, Dimethyladenosine, Functional signature ontology",
author = "Vaden, {Rachel M.} and Oswald, {Nathaniel W.} and Potts, {Malia B.} and MacMillan, {John B.} and White, {Michael A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.3390/md15030075",
language = "English (US)",
volume = "15",
journal = "Marine Drugs",
issn = "1660-3397",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - FUSION-guided hypothesis development leads to the identification of N6,N6-dimethyladenosine, a marine-derived AKT pathway inhibitor

AU - Vaden, Rachel M.

AU - Oswald, Nathaniel W.

AU - Potts, Malia B.

AU - MacMillan, John B.

AU - White, Michael A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harnessing this diversity for biomedical benefit is limited by challenges associated with natural product purification and determination of biochemical mechanism. Using Functional Signature Ontology (FUSION), we report the parallel isolation and characterization of a marine-derived natural product, N6,N6-dimethyladenosine, that robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. Upon validation of the elucidated structure by comparison with a commercially available sample, experiments were initiated to understand the small molecule's breadth of effect in a biological setting. One such experiment, a reverse phase protein array (RPPA) analysis of >50 kinases, indicated a specific cellular response to treatment. In all, leveraging the FUSION platform allowed for the rapid generation and validation of a biological mechanism of action hypothesis for an unknown natural product and permitted accelerated purification of the bioactive component from a chemically complex fraction.

AB - Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harnessing this diversity for biomedical benefit is limited by challenges associated with natural product purification and determination of biochemical mechanism. Using Functional Signature Ontology (FUSION), we report the parallel isolation and characterization of a marine-derived natural product, N6,N6-dimethyladenosine, that robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. Upon validation of the elucidated structure by comparison with a commercially available sample, experiments were initiated to understand the small molecule's breadth of effect in a biological setting. One such experiment, a reverse phase protein array (RPPA) analysis of >50 kinases, indicated a specific cellular response to treatment. In all, leveraging the FUSION platform allowed for the rapid generation and validation of a biological mechanism of action hypothesis for an unknown natural product and permitted accelerated purification of the bioactive component from a chemically complex fraction.

KW - AKT

KW - Dimethyladenosine

KW - Functional signature ontology

UR - http://www.scopus.com/inward/record.url?scp=85016501105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016501105&partnerID=8YFLogxK

U2 - 10.3390/md15030075

DO - 10.3390/md15030075

M3 - Article

VL - 15

JO - Marine Drugs

JF - Marine Drugs

SN - 1660-3397

IS - 3

M1 - 75

ER -